Heerma Peter
Known title: Chief Commercial OfficerCIK: 0001789617
Associated companies
Transaction History
| TVTX | ▲ Buy | Option Exercise | 8,282 | $186K | 9/17/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 8,282 | $539K | 9/17/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 93,604 | $5.9M | 9/16/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 79,113 | $5.0M | 9/16/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 100,000 | $1.1M | 9/16/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 55,000 | $850K | 9/16/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 17,717 | $476K | 9/16/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 39,283 | $1.1M | 9/15/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 1,381 | $31K | 9/15/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 36,526 | $326K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 71,938 | $4.5M | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 27,421 | $1.7M | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,400 | $89K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,431 | $93K | 9/15/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,174 | $101K | 5/5/2026 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 4,250 | $0 | 5/4/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 7,215 | $303K | 4/14/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 14,000 | $0 | 4/13/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 7,310 | $235K | 2/3/2026 | View on chart |
| TVTX | ▲ Buy | Grant | 26,120 | $0 | 1/31/2026 | View on chart |
| TVTX | ▼ Sell | Open Market | 4,980 | $199K | 12/24/2025 | View on chart |
| TVTX | ▼ Sell | Gift | 1,078 | $0 | 11/3/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 5,591 | $196K | 10/31/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,662 | $80K | 10/28/2025 | View on chart |
| TVTX | ▼ Sell | Gift | 891 | $0 | 9/23/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,771 | $37K | 5/5/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 4,920 | — | 5/2/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,568 | $60K | 2/12/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,074 | $77K | 2/11/2025 | View on chart |
| TVTX | ▲ Buy | Option Exercise | 8,000 | — | 2/10/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 5,166 | $104K | 2/3/2025 | View on chart |
| TVTX | ▲ Buy | Grant | 21,500 | $0 | 1/31/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,584 | $30K | 1/22/2025 | View on chart |
| TVTX | ▼ Sell | Open Market | 2,191 | $25K | 9/9/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 6,750 | $0 | 9/5/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 4,195 | $36K | 2/1/2024 | View on chart |
| TVTX | ▲ Buy | Grant | 25,000 | $0 | 1/31/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,559 | $14K | 1/23/2024 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,091 | $26K | 10/3/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,779 | $39K | 2/1/2023 | View on chart |
| TVTX | ▲ Buy | Grant | 20,250 | $0 | 1/31/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,550 | $34K | 1/24/2023 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,042 | $78K | 10/4/2022 | View on chart |
| TVTX | ▲ Buy | Grant | 9,840 | $0 | 1/31/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,125 | $31K | 1/31/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 1,875 | $47K | 1/24/2022 | View on chart |
| TVTX | ▼ Sell | Open Market | 3,058 | $76K | 10/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Travere Shares Drop 6.7% Ahead of New FILSPARI Data
Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.
Travere Shares Drop 6.7% Ahead of New FILSPARI Data. Travere Therapeutics shares fell 6.7% following the release of new data and a patent extension for its drug FILSPARI. The company is set to present results supporting FILSPARI as a foundational treatment for IgA Nephropathy and FSGS at the upcoming ASN Kidney Week 2026. These developments provide key context for investors evaluating the drug's long-term clinical value.